

About BioSyent

Listed on the Toronto Venture Exchange under the trading symbol "RX", BioSyent is a profitable growth oriented specialty pharmaceutical company which searches the globe to in-license or acquire innovative pharmaceutical products that have been successfully developed, are safe and effective, and have a proven track record of improving the lives of patients and supporting the healthcare professionals that treat them. These products occupy a niche in the market, provide novel technological or therapeutic advantages, are unique due to the complexity of the manufacturing process, and are backed by strong partners who hold intellectual property rights that are defensible. BioSyent is focused on Canada and certain other international regions.

Once a product of interest has been found, BioSyent acquires the exclusive rights to the product and manages it through the governmental regulatory approval process. Once approved, BioSyent commercializes the product throughout the territories.

BioSyent's business model is structured to minimize risk and to produce consistent growth, profitably. For the three years ending December 31, 2016 the Company experienced a compound annual revenue growth rate (CAGR) of 32% while delivering a NIAT CAGR of 31% during the same period.

At A Glance - Financial Information

Revenue

2012	\$ 5,024,154
2013	\$ 7,799,426
2014	\$12,211,127
2015	\$15,388,196
2016	\$17,922,270

Cash Generation

2012	\$ 1,258,009
2013	\$ 2,065,082
2014	\$ 2,608,034
2015	\$ 1,726,366
2016	\$ 4,023,810


Net Income After Tax

2012	\$ 1,541,317
2013	\$ 1,928,028
2014	\$ 3,154,079
2015	\$ 3,764,889
2016	\$ 4,309,505

Earnings Per Share (Diluted)

2012	\$ 0.11
2013	\$ 0.13
2014	\$ 0.22
2015	\$ 0.26
2016	\$ 0.30

Pharmaceutical sales growth



At A Glance - Stock Information

Exchange & Trading Symbol:	TSXV: RX
Recent Closing Price (10/11/2017):	\$10.30
52 Week High / Low:	\$11.00 / \$6.90
Current Shares:	14,491,295
Warrants:	0
Options (10/11/2017):	150,495
Fully Diluted (10/11/2017):	14,641,790

BioSyent's Products

Domestic Market

Marketed Products	8
Pre-approval Products	3

International Market

International Markets Signed	10
Brand Sold In	6

Contact Information

Investor Relations

☎ 905.206.0013 x323
@ Investors@BioSyent.com
🌐 www.BioSyent.com

Address

170 Attwell Drive, Suite 520
Toronto, Ontario
M9W 5Z5, Canada



For the fifth consecutive year in 2017, BioSyent was named as one of Canada's fastest growing companies in the PROFIT 500 rankings with a 5 year growth rate of 538% and ranked 132nd on the 2017 PROFIT 500 list.